Travere Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Travere Therapeutics, Inc. (TVTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
Quick Answer
Are TVTX insiders buying or selling?
Travere Therapeutics, Inc. insiders reported 0 open-market buys ($0) and 257 sells ($61.6M) across 257 Form 4 filings — a net selling position of $61.6M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 16, 2026)
Insider sentiment
Net sellingNet insider flow of $61.6M in net selling.
Recent TVTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Timothy Coughlin | Director | Sale | 10.0K | $50.07 | $500.7K |
| Jun 16, 2026 | Roy D. Baynes | Director | Sale | 4.5K | $50.00 | $225.0K |
| May 19, 2026 | Timothy Coughlin | Director | Sale | 3.3K | $43.49 | $141.3K |
| May 7, 2026 | Roy D. Baynes | Director | Sale | 4.5K | $46.65 | $209.9K |
| May 7, 2026 | Meckler Jeffrey A | Director | Sale | 8.0K | $45.00 | $360.0K |
| May 7, 2026 | William E. Rote | Chief Research Officer | Sale | 2.8K | $43.95 | $121.4K |
| May 7, 2026 | Elizabeth E Reed | Chief Legal Officer and GC | Sale | 24.3K | $45.06 | $1.1M |
| May 7, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale | 22.5K | $45.15 | $1.0M |
| May 7, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale | 2.2K | $46.65 | $101.4K |
| May 7, 2026 | Eric M Dube | CHIEF EXECUTIVE OFFICER | Sale | 22.5K | $43.95 | $988.9K |
| May 7, 2026 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sale | 2.5K | $46.31 | $115.4K |
| May 4, 2026 | Roy D. Baynes | Director | Sale | 9.8K | $44.22 | $431.1K |
| Apr 23, 2026 | William E. Rote | Chief Research Officer | Sale | 9.1K | $39.09 | $355.7K |
| Apr 16, 2026 | LYONS GARY A | Director | Sale | 8.0K | $41.07 | $328.6K |
| Apr 16, 2026 | Roy D. Baynes | Director | Sale | 32.8K | $41.29 | $1.4M |
| Apr 16, 2026 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sale | 22.0K | $41.07 | $902.6K |
| Apr 16, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale | 7.2K | $41.93 | $302.5K |
| Apr 16, 2026 | Eric M Dube | CHIEF EXECUTIVE OFFICER | Sale | 64.0K | $41.09 | $2.6M |
| Apr 16, 2026 | Elizabeth E Reed | Chief Legal Officer and GC | Sale | 51.5K | $41.29 | $2.1M |
| Apr 16, 2026 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sale | 8.3K | $41.91 | $349.0K |
| Apr 16, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale | 8.2K | $42.01 | $345.9K |
| Apr 7, 2026 | Roy D. Baynes | Director | Sale | 10.0K | $33.00 | $330.0K |
| Apr 2, 2026 | Eric M Dube | CHIEF EXECUTIVE OFFICER | Sale | 60.0K | $30.93 | $1.9M |
| Apr 2, 2026 | Elizabeth E Reed | Chief Legal Officer and GC | Sale | 10.0K | $30.00 | $300.0K |
| Mar 18, 2026 | Elizabeth E Reed | Chief Legal Officer and GC | Sale | 10.0K | $28.09 | $280.9K |
Showing the 25 most recent of 257 Form 4 filings for Travere Therapeutics, Inc..
Most active TVTX insiders
- Elizabeth E Reed40 filings
- William E. Rote35 filings
- Eric M Dube30 filings
- Steve Aselage25 filings
- Peter Heerma24 filings
Ask anything about TVTX insider activity
Use Trabud's AI agent to query Travere Therapeutics, Inc.'s Form 4 history in plain English — "Show me TVTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentTVTX insider trading FAQ
Are Travere Therapeutics, Inc. insiders buying or selling?
Across 257 SEC Form 4 filings, Travere Therapeutics, Inc. (TVTX) insiders reported 0 open-market purchases totaling $0 and 257 sales totaling $61.6M. That is a net selling position of $61.6M.
How many insiders trade TVTX stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Travere Therapeutics, Inc.. The most recent filing was accepted on Jun 16, 2026.
Where does Trabud get TVTX insider trading data?
All TVTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.